Media coverage about Calithera Biosciences (NASDAQ:CALA) has been trending somewhat positive recently, according to Accern Sentiment. Accern identifies negative and positive press coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Calithera Biosciences earned a coverage optimism score of 0.13 on Accern’s scale. Accern also assigned media stories about the biotechnology company an impact score of 47.0512046677883 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
Here are some of the news articles that may have effected Accern’s rankings:
- If you follow the Recipe you will get the best result- The Goodyear Tire & Rubber Company (NASDAQ:GT), Gold Fields … (thestreetpoint.com)
- Top Gainer of Thursday: Calithera Biosciences, Inc. (CALA) stock price finalizes at $4.53 with positive performance of … (topdesertsafari.com)
- Top Negative Stock: Calithera Biosciences, Inc. (CALA) stock price completes at $5.10 with down move of 14.61% on … (topdesertsafari.com)
- Calithera Biosciences, Inc. (CALA)- Investor’s Alert (Profitability Ratios Analysis) (topdesertsafari.com)
- Calithera Biosciences (CALA) Issues Quarterly Earnings Results, Beats Estimates By $0.23 EPS (americanbankingnews.com)
CALA stock traded down $0.08 during trading on Friday, reaching $4.45. The company had a trading volume of 243,802 shares, compared to its average volume of 345,374. The stock has a market capitalization of $162.84 million, a PE ratio of -5.30 and a beta of 2.38. Calithera Biosciences has a twelve month low of $4.05 and a twelve month high of $18.35.
Calithera Biosciences (NASDAQ:CALA) last announced its quarterly earnings data on Tuesday, August 7th. The biotechnology company reported ($0.09) EPS for the quarter, beating the consensus estimate of ($0.32) by $0.23. The business had revenue of $17.07 million during the quarter, compared to analysts’ expectations of $5.17 million. Calithera Biosciences had a negative net margin of 90.65% and a negative return on equity of 22.09%. sell-side analysts anticipate that Calithera Biosciences will post -1.27 earnings per share for the current year.
A number of brokerages have recently issued reports on CALA. Zacks Investment Research raised shares of Calithera Biosciences from a “sell” rating to a “hold” rating in a research report on Tuesday, May 15th. ValuEngine cut shares of Calithera Biosciences from a “sell” rating to a “strong sell” rating in a research note on Wednesday. Three analysts have rated the stock with a sell rating and three have issued a buy rating to the company. The stock presently has an average rating of “Hold” and an average target price of $16.50.
Calithera Biosciences Company Profile
Calithera Biosciences, Inc is a clinical-stage biopharmaceutical company, which engages in discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer. It offers programs such as Pipeline, Glutaminase Inhibitor, and Arginase Inhibitor.
Further Reading: Using the New Google Finance Tool
Receive News & Ratings for Calithera Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calithera Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.